{"id":1515792,"date":"2024-08-22T14:03:08","date_gmt":"2024-08-22T12:03:08","guid":{"rendered":"https:\/\/laboklin.com\/esami\/patologia\/tumour-genetic-tests\/molecular-genetic-tumour-panel-dog\/"},"modified":"2026-02-27T09:09:51","modified_gmt":"2026-02-27T08:09:51","slug":"molecular-genetic-tumour-panel-dog","status":"publish","type":"page","link":"https:\/\/laboklin.com\/it\/esami\/patologia\/esami-genetici-tumorali\/molecular-genetic-tumour-panel-dog\/","title":{"rendered":"Molecular Genetic Tumour Panel (dog)"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text css=””]

Molecular Genetic Tumour Panel (dog)<\/h3>

LABOKLIN Service ID: 1258<\/span><\/p>


Panel for a more precise characterisation of malignant tumours in dogs in selected cases:

Therapeutic indications<\/strong>

  • No known or conventional treatment concepts<\/li>
  • (Treatment-resistant) recurrence<\/li>Genome-based individualised treatment may potentially offer a new therapeutic option (please pay attention to the European Cascade Rule, if applicable).

    Diagnostic indication<\/strong>
  • A reliable cytological or (immuno)histological diagnosis was not possible.<\/li>
  • The molecular genetic signature can help to further refine the diagnosis (e.g. histiocytic neoplasia versus inflammation), and possibly a therapeutic option may also be identified.<\/li><\/p>
    Material<\/strong><\/td>

  • 15 smears rich in tumour cells (not covered)<\/li>
  • Biopsies > 0.5 cm (formalin-fixed)<\/li>
  • Tumour resections (formalin-fixed)<\/li>
  • Paraffin blocks with sufficient tumour material (paraffin rolls or decalcified tissue are\r\nnot suitable)<\/li><\/ul><\/p><\/td><\/tr>
    • Parameter<\/strong><\/td>

    Analysis of approximately 20,000 genes for mutations<\/p><\/td><\/tr>

    Method<\/strong><\/td>

    Next Generation Sequencing (NGS) (VetOmics, Canine CGP\u00ae)<\/p><\/td><\/tr>

    Species list<\/strong><\/td>

    Dog<\/p><\/td><\/tr>

    Duration<\/strong><\/td>

    Approx. 3 weeks <\/p><\/td><\/tr>

    Remark<\/strong><\/td>

  • Summary of the molecular genetic results<\/li>
  • Explanations and literature references on the biomarkers found<\/li>
  • Specification of the tumour mutation burden to predict response to checkpoint inhibitors (e.g. PD-1, PDL-1 inhibitors, APAVAC)<\/li>
  • Suitable drugs for individualised tumour treatment are suggested, along with dosages and information on the level of evidence.<\/li>
  • If required, further advice on the treatment options identified is provided directly by the oncologists in the USA via email (in English).<\/li>
    Limitations<\/strong>
  • A sufficient number of tumour cells and DNA quality are required<\/li>
  • It is not always possible to isolate DNA in sufficient quantity and quality<\/li>
  • It is not always possible to find mutations that open up therapeutic options.<\/li>
  • The availability and costs of medication may vary between countries.<\/li>
  • The drugs may not be approved for dogs in all countries.<\/li>
  • The efficacy of these medications in dogs is supported by varying degrees of evidence<\/li>
  • Data on effectiveness and side effects in the respective canine tumours is often incomplete.<\/li>
    The decision and responsibility for using the medication listed in the findings lies with the veterinarian in charge! It is recommended to consult a specialised oncologist in such cases.<\/p><\/td><\/tr><\/table>
    <\/div>\n

    [\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

    [vc_row][vc_column][vc_column_text css=””] [\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":1383314,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1515792","page","type-page","status-publish","hentry","description-off"],"_links":{"self":[{"href":"https:\/\/laboklin.com\/it\/wp-json\/wp\/v2\/pages\/1515792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/laboklin.com\/it\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/laboklin.com\/it\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/laboklin.com\/it\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/laboklin.com\/it\/wp-json\/wp\/v2\/comments?post=1515792"}],"version-history":[{"count":2,"href":"https:\/\/laboklin.com\/it\/wp-json\/wp\/v2\/pages\/1515792\/revisions"}],"predecessor-version":[{"id":1542649,"href":"https:\/\/laboklin.com\/it\/wp-json\/wp\/v2\/pages\/1515792\/revisions\/1542649"}],"up":[{"embeddable":true,"href":"https:\/\/laboklin.com\/it\/wp-json\/wp\/v2\/pages\/1383314"}],"wp:attachment":[{"href":"https:\/\/laboklin.com\/it\/wp-json\/wp\/v2\/media?parent=1515792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}